Bio Green Med Solution, Inc. (BGMS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 700K 1.4M 2.1M Q2 '14: 1.4M Q3 '14: 1.8M Q4 '14: 1.7M Q1 '15: 1.9M Q2 '15: 1.8M Q3 '15: 1.8M Q4 '15: 1.9M Q1 '16: 1.6M Q2 '16: 1.5M Q3 '16: 987K Q4 '16: 843K Q1 '17: 704K Q2 '17: 482K Q3 '17: 277K Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 150K Q1 '19: 150K Q2 '19: 150K Q3 '19: 150K Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 373K Q3 '23: 389K Q4 '23: 420K Q1 '24: 449K Q2 '24: 80K Q3 '24: 74K Q4 '24: 43K Q2 '26: 1.9M Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '21 Q3 '22 Q4 '23 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '16: -14.8M Q4 '16: -14.2M Q1 '17: -13.1M Q2 '17: -11.8M Q3 '17: -10.5M Q4 '17: -9.5M Q1 '18: -9M Q2 '18: -8.9M Q3 '18: -9.3M Q4 '18: -9.5M Q1 '19: -9.6M Q2 '19: -9.5M Q3 '19: -9.4M Q4 '19: -9.7M Q1 '20: -9.9M Q2 '20: -10M Q3 '20: -10.3M Q4 '20: -10.6M Q1 '21: -12.5M Q2 '21: -16.1M Q3 '21: -19.6M Q4 '21: -22.7M Q1 '22: -24.9M Q2 '22: -24.6M Q3 '22: -25.1M Q4 '22: -27.7M Q1 '23: -28.4M Q2 '23: -28.6M Q3 '23: -28.9M Q4 '23: -25.5M Q1 '24: -22.5M Q2 '24: -20.2M Q3 '24: -15.5M Q4 '24: -12M Q1 '25: -8.5M Q2 '25: -4.9M Q3 '25: -3.7M Q4 '25: -3M Q1 '26: -2.4M Q2 '26: -2.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '16: -12.3M Q4 '16: -11.8M Q1 '17: -10.3M Q2 '17: -9.5M Q3 '17: -8.4M Q4 '17: -7.5M Q1 '18: -7.3M Q2 '18: -6.9M Q3 '18: -7.1M Q4 '18: -7.3M Q1 '19: -7.8M Q2 '19: -7.7M Q3 '19: -7.5M Q4 '19: -7.8M Q1 '20: -7.2M Q2 '20: -7.6M Q3 '20: -7.9M Q4 '20: -8.4M Q1 '21: -10.7M Q2 '21: -13.7M Q3 '21: -16.4M Q4 '21: -18.7M Q1 '22: -19.3M Q2 '22: -18.8M Q3 '22: -18.9M Q4 '22: -21.2M Q1 '23: -22.9M Q2 '23: -23.8M Q3 '23: -24.7M Q4 '23: -22.6M Q1 '24: -19.7M Q2 '24: -17.5M Q3 '24: -13.4M Q4 '24: -11.2M Q1 '25: -8.3M Q2 '25: -6.4M Q3 '25: -5.4M Q4 '25: -3M Q1 '26: -3.1M Q2 '26: -2.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '16: -9.8M Q4 '16: -10.1M Q1 '17: -10.7M Q2 '17: -9.9M Q3 '17: -8.2M Q4 '17: -7.5M Q1 '18: -5.8M Q2 '18: -7.4M Q3 '18: -6.9M Q4 '18: -6.7M Q1 '19: -8.2M Q2 '19: -9.1M Q3 '19: -10.4M Q4 '19: -9.4M Q1 '20: -8.6M Q2 '20: -7.8M Q3 '20: -7.9M Q4 '20: -7.9M Q1 '21: -8.7M Q2 '21: -11.1M Q3 '21: -15.1M Q4 '21: -18.5M Q1 '22: -21.7M Q2 '22: -19.4M Q3 '22: -20.2M Q4 '22: -20.8M Q1 '23: -20.9M Q2 '23: -20.3M Q3 '23: -17.4M Q4 '23: -16.1M Q1 '24: -9.7M Q2 '24: -11.5M Q3 '24: -10.5M Q4 '24: -8M Q1 '25: -10.8M Q2 '25: -8.7M Q3 '25: -6.1M Q4 '25: -4.8M Q1 '26: -1.8M Q2 '26: -1.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q2 '12: -13M Q3 '12: -12.9M Q4 '12: -12.1M Q1 '13: -13.7M Q2 '13: -15.3M Q3 '13: -15.4M Q4 '13: -18.4M Q1 '14: -17.7M Q2 '14: -16.5M Q3 '14: -20.8M Q4 '14: -19M Q1 '15: -19.2M Q2 '15: -17.8M Q3 '15: -15.5M Q4 '15: -14.5M Q4 '17: -7.5M Q1 '18: -5.8M Q2 '18: -7.5M Q3 '18: -6.9M Q4 '18: -6.7M Q1 '19: -8.3M Q2 '19: -9.1M Q3 '19: -10.4M Q4 '19: -9.5M Q1 '20: -8.6M Q2 '20: -7.8M Q3 '20: -8M Q4 '20: -8M Q1 '21: -8.9M Q2 '21: -11.2M Q3 '21: -15.2M Q4 '21: -18.6M Q1 '22: -21.8M Q2 '22: -19.5M Q3 '22: -20.2M Q4 '22: -20.8M Q1 '23: -20.9M Q2 '23: -20.3M Q3 '23: -17.4M Q4 '23: -16.1M Q2 '13 Q3 '14 Q4 '15 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '10: 36.6M Q3 '10: 37M Q1 '11: 46.6M Q2 '11: 46.6M Q3 '11: 7.7M Q1 '12: 7.8M Q2 '12: 8.4M Q3 '12: 8.4M Q1 '13: 9.8M Q2 '13: 13.9M Q3 '13: 17.8M Q1 '14: 19.5M Q2 '14: 22.6M Q1 '21: 7M Q2 '21: 9.2M Q3 '21: 9.4M Q1 '22: 10M Q2 '22: 10.1M Q3 '22: 12.3M Q1 '23: 12.5M Q2 '23: 12.6M Q3 '24: 44.7K Q1 '25: 365.2K Q2 '25: 1.4M Q3 '25: 1.9M Q1 '26: 5.5M Q2 '26: 5.6M Q1 '11 Q2 '12 Q3 '13 Q2 '21 Q3 '22 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-240.00 -160.00 -80.00 0.00 80.00 160.00 240.00 Q2 '14: -0.92 Q3 '14: -0.82 Q4 '14: -0.90 Q1 '15: -0.84 Q2 '15: -1.81 Q3 '15: -2.54 Q4 '15: -3.49 Q1 '16: -4.34 Q2 '16: -4.16 Q3 '16: -4.07 Q4 '16: -3.52 Q1 '17: -2.86 Q2 '17: -2.35 Q3 '17: -2.40 Q4 '17: -1.95 Q1 '18: -1.69 Q2 '18: -1.35 Q3 '18: -0.62 Q4 '18: -0.63 Q1 '19: -3.28 Q2 '19: -5.25 Q3 '19: -7.34 Q4 '19: -9.93 Q1 '20: -8.64 Q2 '20: -7.09 Q3 '20: -5.29 Q4 '20: -4.14 Q1 '21: -3.16 Q2 '21: -3.14 Q3 '21: -3.21 Q4 '21: -2.11 Q1 '22: -2.03 Q2 '22: -1.93 Q3 '22: -1.81 Q4 '22: -27.25 Q4 '24: -230.70 Q1 '25: -228.43 Q2 '25: -57.23 Q3 '25: -14.74 Q4 '25: -5.88 Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.